Prognosis in chronic myelomonocytic leukemia (CMML) is unfavorable and the optimal therapy remains uncertain. Currently, allogeneic stem cell transplantation is the only known curative therapeutic option. However, the data available are limited and restricted to small retrospective series. There is even less information on the use of donor lymphocyte infusions (DLI) for this disease. We reviewed our experience of allogeneic stem cell transplantation and DLI for adults with CMML. Seventeen consecutive adults underwent allogeneic stem cell transplantation from related (n ¼ 14) or unrelated (n ¼ 3) donors. Median age was 50 years (range 26-60). Seven patients (41%) demonstrated relapse or persistent disease at a median of 6 months (range 3-55.5). Five patients underwent DLI for morphologic relapse and one for mixed donor chimerism. Two patients achieved durable complete remissions of 15 months each. The overall transplantrelated mortality was 41% (n ¼ 7). With a median followup of 34.5 months, three patients (18%) currently remain alive and in continuous CR. The current study demonstrates a graft-versus-leukemia effect in CMML, both for allogeneic stem cell transplantation and for DLI. Nevertheless, consistent with reported experience of others, overall outcomes remain less than optimal and unpredictable.
Introduction
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder characterized by an absolute peripheral blood monocytosis accompanied by evidence of both effective (myeloproliferative) and ineffective (myelodysplastic) hematopoiesis. The coexistence of these contrasting features prompted the formation of a new category in the WHO classification of myeloid disorders 'myelodysplastic/myeloproliferative diseases (MDS/ MPD)', which has provided some resolution to concerns in the previous classification of CMML counting as one of the myelodysplastic syndromes. Diagnostic features include peripheral blood monocytosis of greater than 1 Â 10 9 /l, peripheral blood blasts of less than 5%, bone marrow (BM) blasts of 20% or less, absence of Auer rods, and dysplastic features in at least one hematopoietic cell precursor lineage in the marrow. Furthermore, CMML has been divided into two prognostically relevant subcategories on the basis of blast percentage in blood and marrow CMML-1 (blood: o5% and marrow: o10%) and CMML-2 (blood: 5-19% and marrow: 10-19%), respectively. This is based on the recognition that virtually all studies to date have identified the percentage of blasts to be one of the most important factors in determining survival. 1 The overall prognosis in CMML is unfavorable, with reported median survivals of 12-19 months, and the optimum therapy remains uncertain. 2, 3 There is a paucity of clinical trial data specific for CMML. 4 Current management decisions are based on studies, which included patients with CMML in large studies for patients with MDS, a group now felt to biologically represent a different disease process. 1 Allogeneic stem cell transplantation is currently the only known curative therapeutic option. [5] [6] [7] However, the data available are limited and retrospective, with the largest study comprising only 50 patients. 5 This retrospective report on behalf of the European Group for Blood and Marrow Transplantation (EBMT) reported 5-year estimated overall (OS) and disease-free (DFS) survivals of 21 and 18%, respectively. 5 Poor outcomes were largely due to the competing risks of transplant-related mortality (TRM) (52%) and relapse (49%). Recently updated retrospective data from the Fred Hutchinson Cancer Research Center are somewhat more encouraging, reporting 4 year OS and DFS of 41%, yet with TRM and relapse of 34 and 23%, respectively. 7 However, this series included infants and children, and so is not entirely comparable. Data on donor lymphocyte infusion (DLI) for CMML are also limited and evidence for a graft-versus-leukemia effect is based on retrospective registry data showing a trend for lower relapse rates in patients with acute graft-versus-host disease (GVHD) and with T-cell-replete grafts. 5 To gain further insight, we retrospectively reviewed our experience of allogeneic stem cell transplantation and DLI for adult (418 years) with CMML.
Patients and methods

Patients
Seventeen consecutive adult patients (11 males) with CMML underwent allogeneic stem cell transplantation between 1992 and 2004 (Table 1) . To avoid overlap with juvenile CML, patients younger than 18 years were excluded from the analysis. At time of transplant, the median age was 50 years (range 26-60) and median duration of disease prior to transplant 7 months (range 2.5-44). At transplantation, the median white blood cell count was 7.6 Â 10 9 /l (range 0.1-36.8) with median monocytes at 17% (range 0-55%). The median peripheral blood blasts were 0.5% (range 0-60) and BM blast count 6% (range 1-58). Prior to transplant, 11 patients had evolved into acute myeloid leukemia (AML). Of these, nine patients received standard AML induction chemotherapy (either idarubicin (n ¼ 7) or daunorubicin (n ¼ 2) daily over 3 days plus continuous infusion cytarabine at 100 mg/m 2 /day over 7 days), but only one patient achieved complete remission (CR). The remaining four had persistent or recurrent CMML, and four had refractory AML. Karyotype at the time of transplant was available for all patients and was either normal (n ¼ 9) or showed isolated monosomy 7 (n ¼ 4), complex (n ¼ 1), or single, nonrecurrent abnormalities (n ¼ 3).
Donor and hematopoietic stem cell characteristics Hematopoietic stem cell donors were human lymphocyte antigen (HLA)-identical siblings for 14 patients and volunteer unrelated donors for the remaining three (two were HLA-identical and one had a single antigen mismatch) ( Table 2 ). Hematopoietic stem cell source was peripheral blood (n ¼ 7), BM (n ¼ 8), or both (n ¼ 2). The median BM mononuclear cell dose was 2.3 Â 10 8 /kg (range (1.7-4.15) and the median peripheral blood CD34 þ cell dose cell/kg 5.12 Â 10 6 /kg (range 0.94-7.29)).
Conditioning regimens and graft-versus-host disease prophylaxis The conditioning regimen was Cytoxan (60 mg/kg once daily i.v. on days 1 and 2 (total dose 120 mg/kg) and total body irradiation at 1320 cGy (n ¼ 12) or 1200 cGy (n ¼ 4) for all but one patient who received an investigational nonmyeloablative regimen of 2-chloro-deoxyadenosine (2-CDA) at 5 mg/m 2 /day on day À10 to day À6, thiotepa 200 mg/m 2 /d on day À5 to day À3 and antithymocyte globulin. Graft-versus-host disease prophylaxis consisted of cyclosporine (CSA) and short course methotrexate (MTX) (n ¼ 12), cyclosporin alone (n ¼ 3), CSA with prednisone (n ¼ 1) or tacrolimus with methotrexate (n ¼ 1). Patients developing grade I acute GVHD with mild involvement of the skin were treated with topical steroids. Patients with more extensive skin involvement or grades II-IV acute GVHD received 1-2 mg/kg/day of methylprednisolone in combination with therapeutic doses of intravenous or oral CSA.
Supportive care
Prophylaxis against bacterial infections consisted of an oral fluoroquinolone and penicillin. Empiric intravenous broad-spectrum antibiotics were started for febrile neutropenia. Antifungal prophylaxis was with fluconazole, and trimethoprim-sulfamethoxazole or inhaled pentamidine provided Pneumocystis prophylaxis. Cytomegalovirus prophylaxis was provided by transfusing CMV negative or leukocyte-reduced blood products. Beginning at engraftment, weekly quantitative blood polymerase chain reaction (PCR) assays were performed for CMV positive recipients or those with a positive donor, and pre-emptive therapy with ganciclovir was begun for CMV viremia. Herpes simplex prophylaxis consisted of oral valacyclovir or intravenous acyclovir.
Statistics
The probabilities of disease-free and OS were estimated by the method of Kaplan-Meier. Multivariate analysis was performed to determine the effect of age, duration of disease, BM blast count, karyotype or induction chemotherapy prior to transplantation on DFS or OS, using the Cox regression model. 8 
Results
Transplantation outcomes are summarized in Table 3 .
Engraftment
All but one patient who died on day þ 11 of sepsis achieved a sustained neutrophil count of 40.5 Â 10 9 /l at a median of 19.5 days (range 13-31).
Graft-versus-host disease
Among the 16 patients achieving sustained engraftment, the incidence of acute GVHD grade II-IV and III-IV was 75% (12/16) and 37.5% (6/16), respectively. Extensive chronic GVHD (CGVHD) developed in six of 15 (40%) who were at risk for this complication (surviving beyond day 100).
Relapse and management
Seven patients (41%) demonstrated relapse or persistent disease at a median of 6 months (range 3-55.5) and all seven patients who relapsed have died as a result. Survival after relapse was generally brief, at a median of 3 months (range 0.25-18.5). Management of relapse with curative intent included rapid tapering of immunosuppressants (where applicable) with subsequent DLI (n ¼ 6) and highdose cytarabine followed by a second myeloablative sibling donor stem cell transplant (n ¼ 1). The latter patient had relapsed 55.5 months following allogeneic stem cell transplantation. High-dose cytarabine failed to induce a second remission and the patient underwent a second, full myeloablative transplant from the same donor, with residual disease. A second remission was achieved but maintained for only 4 months post transplant and subsequent salvage therapy with DLI was unsuccessful. The patient died of relapsed disease 9 months after the second transplant.
Donor lymphocyte infusions
Five patients underwent DLI for morphologic relapse (four recurrent/persistent CMML, one AML) and one for cytogenetically defined mixed donor chimerism (14 metaphases of which 12 were female donor, and two were male recipient), at a median of 19.5 days (range 6-52) post relapse and 118 days (range 76-738) post-transplantation (Table 4) . No patients had evidence of active GVHD at the time of relapse and DLI. Available chimerism data at the time of relapse and DLI are presented in Table 4 . The median BM blast count at DLI was 3% (1-22%). The median CD3 þ cell dose infused was 30.45 Â 10 7 cells/kg (11.2-45.5), given in a median of three infusions (range 1-3). Two patients (one with mixed donor chimerism and one with morphologic relapse) achieved durable, CRs of 15 months each. Both patients developed extensive CGVHD, and infectious complications of which led to death of one. The other relapsed but failed to respond to a second DLI and died of disease 2 months later. The remaining four patients did not achieve a second remission after DLI. Three showed progressive disease and one died of bacterial sepsis in association with pancytopenia and grade IV acute GVHD, but without evidence of residual leukemia in the BM, 1 month after DLI.
Transplant-related mortality
Seven patients (41.2%) died at a median of 6 months (range 0.33-36.5). Causes of death included GVHD with infection (n ¼ 4) or with gastrointestinal hemorrhage (n ¼ 1), bacterial sepsis (n ¼ 1) and multiorgan failure (n ¼ 1) (Table 5 ).
Survival and cause of death
Fourteen patients (82%) have died due to relapsed disease, complications of treatment of relapse (41%) or directly from complications related to transplantation (41%).
With a median follow-up of 34.5 months, three patients currently remain alive, all of whom are in continuous CR (18%), at 16, 34.5 (treated with the NMA regimen) and 116 months, respectively. For the entire cohort, median DFS and OS were 6 and 7 months, respectively. Survival at day 100 was 88.2%. The OS and disease-free survival (DFS) at 3 years was 18% with a median DFS and OS of 6 and 7 months, respectively. Of the three patients surviving in remission, all had transformed to AML prior to allogeneic stem cell transplantation, but only one had achieved CR following AML induction chemotherapy.
Multivariate analysis failed to demonstrate any significant effect on DFS or OS of age, duration of disease, BM blast count, karyotype or induction chemotherapy prior to transplantation, likely reflecting the small numbers available for analysis.
Discussion
Overall prognosis of CMML is poor. Recently, the MD Anderson group published a new scoring system derived from the study of the largest population (n ¼ 213) of CMML patients used for this purpose. 2 The scoring system developed identifies four risk groups (low, intermediate I, intermediate II and high), according to the following four independent adverse prognostic features: hemoglobin o12 g/dl, an absolute lymphocyte count 42.5 Â 10 9 /l, presence of circulating immature myeloid cells and marrow blasts of X10%.
2 Median survival for the entire population was only 12 months. By the summation of a single point for each adverse prognostic factor, four risk groups with median survivals of 24, 15, 8 and 5 months are predicted. 2 A recent update of survival data on a cohort of 288 CMML patients included in the Dusseldorf MDS Registry reported a median survival of 19 months. 3 The only known curative therapy for CMML is allogeneic hematopoietic stem cell transplantation. In spite of this fact, there are relatively few studies that specifically report on transplant outcomes for this disease. Reasons for this paucity of data relate to the fact that many patients so managed were included within larger series of MDS patients, which did not provide specific outcome data for CMML, which has only recently been reclassified as a distinct clinical entity. 1,9,10 Furthermore, the advanced median age at presentation (range 65-75 years in reported series) of this population has also impacted upon the number of candidates for this procedure.
3,11 A summary of outcomes of allogeneic stem cell transplantation of the few studies that report specifically for CMML patients is provided in Table 6 . [5] [6] [7] 12 As can be seen from this limited data set, although allogeneic stem cell transplantation has the potential to induce durable DFS, the majority of recipients succumb either to TRM or disease relapse. Results from other centers reflect a similar experience to ours. Kroger et al., on behalf of the European Group for Blood and Marrow Transplantation (EBMT), reported the largest series of CMML patients to date. 5 This series Twenty-six patients (52%) died of treatment-related causes. After a median follow-up of 40 months, the 5 year estimated OS and DFSs were 21 and 18%, respectively, with an estimated probability of relapse of 49%. 5 Kerbauy et al. 7 reported the largest single institution experience of allogeneic transplantation for CMML. A total of 43 patients underwent allogeneic transplantation from related (n ¼ 21) or unrelated (n ¼ 22) donors between 1990 and 1998. One-third of patients died of treatment-related causes and the 4 year estimated overall and relapse-free survival was 41% with a nonrelapse mortality of 34%. 7 Although these results appear more encouraging, as is typical when comparing single institution to registry data, the report by Kerbauy et al. included infants and children, and therefore is not entirely representative. Regardless, current reported outcomes of allogeneic transplantation remain less than optimal. Whether nonmyeloablative allogeneic transplantation will have the ability to overcome inherent disease resistance, while simultaneously reducing nonrelapse mortality, remains to be seen. Studies specifically addressing non-myeloablative allogeneic stem cell transplantation to date have included only a limited number of CMML patients, and follow-up at this time is short. 13 Certainly if efficacious, it would likely increase the therapeutic options for these typically older patients, for whom standard myeloablative regimens are prohibitively toxic.
In spite of intensive conditioning, the incidence of relapse is high, ranging from approximately 25-60%. Options for relapsed disease are few, although DLI have the potential to induce durable second remissions, consistent with a graft-versus-leukemia effect. In our series, a durable second remission of 15 months was achieved with DLI for frank morphologic relapse of CMML, occurring at 3 months post-transplant. A second patient with mixed donor chimerism at day þ 76 achieved full donor chimerism, which was also durable. A third patient was rendered free of morphologic disease following DLI for hematologic relapse at 23 months, but died of infectious complications resulting from pancytopenia associated with the donor lymphocyte-induced acute GVHD, without meeting the criteria for response. Nevertheless, these three cases do provide evidence of a graft-versus-leukemia effect in CMML. Harnessing this in combination with improved conditioning (such as non myeloablative or reducedintensity regimens) may provide one means to improve transplant outcomes for these patients.
Summary and conclusion
The current study demonstrates a graft-versus-leukemia effect in CMML, both for allogeneic stem cell transplantation and DLI. Nevertheless, overall outcomes remain less than optimal and unpredictable. Novel approaches are urgently needed. In the foreseeable future, this will most likely be provided in the form of reduced intensity conditioning regimens, with associated reduced transplant related mortality, and maximization of the graft-versusleukemia effect to reduce the unacceptably high rates of relapse. This strategy would also increase transplantation options for the typically older CMML patient. Prospective trials to explore this modality are needed, as at this time the potential upfront morbidity and mortality of acute GVHD and the long-term consequences of CGVHD could prove prohibitive. Continued reporting and investigation of specific therapeutic strategies and responses must be encouraged.
